Isang volunteer sa clinical trials ng COVID-19 vaccine sa Brazil nasawi

By Dona Dominguez-Cargullo October 22, 2020 - 06:21 AM

Nasawi ang isa sa mga volunteer na lumahok sa clinical trials ng COVID-19 vaccine na ginagawa ng Oxford University sa Brazil.

Sa kabila nito, sinabi ng mga namamahala sa clinical trials na walang safety concerns at tuloy ang testing ng bakuna ng likha ng pharmaceutical firm na AstraZeneca.

Batay sa ulat, ang volunteer ay isang 28 anyos na doktor at pumanaw ito dahil sa kumplikasyon na dulot ng pagkakaroon niya ng COVID-19.

Ayon sa inilabas na pahayag ng Oxford, walang dapat ikabahala sa safety ng ginagawang clinical trial.

Sinabi rin ng AstraZeneca na base sa ginawa nilang independent review, ang insidente ng pagkasawi ng volunteer ay walang kaugnayan sa nagpapatuloy na trial at pag-aaral sa bakuna.

Hindi naman ito nagbigay ng detalye tungkol sa pumanaw na pasyente dahil kailangan umanong protektahan ang impormasyon tungkol sa kanilang mga volunteer.

Umabot na sa 8,000 volunteers ang nabakunahan sa ginagawang trial sa Brazil.

 

 

 

 

 

TAGS: AstraZeneca, Brazil, clinical trial volunteer, covid 19 vaccine, covid pandemic, COVID-19, department of health, general community quarantine, Health, Inquirer News, Modified enhanced community quarantine, Modified general community quarantine, News in the Philippines, oxford, Radyo Inquirer, State of Emergency, Tagalog breaking news, tagalog news website, AstraZeneca, Brazil, clinical trial volunteer, covid 19 vaccine, covid pandemic, COVID-19, department of health, general community quarantine, Health, Inquirer News, Modified enhanced community quarantine, Modified general community quarantine, News in the Philippines, oxford, Radyo Inquirer, State of Emergency, Tagalog breaking news, tagalog news website

Disclaimer: The comments uploaded on this site do not necessarily represent or reflect the views of management and owner of Cebudailynews. We reserve the right to exclude comments that we deem to be inconsistent with our editorial standards.

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.